The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
Maud A W HermansBenjamin SchrijverConny C P A van Holten-NeelenRoy Gerth van WijkP Martin van HagenPaul L A van DaeleWillem A DikPublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2018)
This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation. This renders the JAK-STAT pathway as an interesting target for therapy to release symptom burden in mastocytosis and many other MC mediator-related diseases.